~The signing of this MoU underscores a long-term commitment to addressing India’s growing respiratory care needs and sets the stage for transformative improvements in the fie

Aerogen, an Ireland-based global leader in acute-care aerosol drug delivery, and Indian Association of Respiratory Care (IARC) signed a MoU to enhance respiratory therapy education and improve patient care across India. This strategic collaboration marks an important day in the development of respiratory care and highlights a shared commitment to elevate respiratory services and outcomes for patients nationwide.

The IARC, representing over 500 Respiratory Therapists, provides education and critical care updates both in India and abroad. With a robust advisory board of leading medical experts, IARC supports respiratory care across hospitals, home care, and training programs. On the other hand, Aerogen prioritizes research and development to innovate its product range and set new standards for quality and efficiency in aerosol drug delivery technology.

This partnership combines Aerogen’s expertise with IARC’s network, focusing on education and training programs to upskill respiratory therapists for the evolving needs of critical care in India.

Debabrata Bhowmick, Commercial Director, Aerogen India, emphasized, “This partnership is pivotal in fostering innovation in respiratory care education and enhancing patient outcomes in India. By merging Aerogen’s technology with IARC’s expertise, we are setting new standards in care while empowering healthcare professionals with the tools and knowledge to excel.”

The partnership will leverage Aerogen’s advanced drug delivery systems to ensure higher-quality care in critical settings, improving patient outcomes and respiratory care services across various healthcare facilities in India.

Delighted to announce this MoU with Aerogen, Dr. Harish Mallapura Maheshwarappa, President of IARC, stated, “This partnership marks a significant milestone in our journey to deliver high-quality respiratory care services. Together, we aim to enhance services, improve patient outcomes through evidence-based practices, and promote research and education.”

Besides training, the collaboration also aims to increase awareness of aerosol and respiratory therapies among healthcare professionals and students, contributing to an improved standard of respiratory care across the country. Dr. Sriharsha Tatineni, Vice President IARC said, “This collaboration is a big step forward in raising awareness among respiratory therapists in India. By equipping healthcare professionals with the right knowledge, tools, and best practices, we are confident that this partnership will elevate respiratory care standards across the country.”

“Aligning with Aerogen’s innovative technology lays the foundation for enhanced patient outcomes and more effective therapies, benefiting countless individuals in need of critical respiratory care.” Dr. Saumy Johnson, General Secretary IARC, further added as she emphasized the impact of the collaboration.

Aerogen entered the Indian market in 2019 with the support of Enterprise Ireland, the Irish government organization responsible for promoting Irish enterprises globally. Ross Curran, Director, India & South Asia, Enterprise Ireland, commented, “Aerogen is the partner of choice for the world’s leading ventilator companies for aerosol drug delivery. We are excited to witness this impactful partnership with IARC. Together, Aerogen’s cutting-edge technology and IARC’s deep understanding of the Indian healthcare landscape will significantly advance training and enhance healthcare infrastructure in India.”

The signing of this MoU reflects a long-term commitment to address India’s growing respiratory care needs, setting the stage for transformative improvements in the field. Aerogen and IARC are positioned to make a significant impact on patient lives and the professional development of healthcare providers in India.